Skip to main content
Full access
Letter
Published Online: 1 February 2001

Risperidone Addition and Psychotic Exacerbation

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
SIR: Some case reports have showed that risperidone can induce notable rage and aggressiveness,1 behavioral stimulation,2 and manic symptoms3,4 in schizophrenia. Risperidone thus may be paradoxically prone to precipitate psychiatric symptoms in some susceptible schizophrenic patients.
In this report, we describe a patient with refractory chronic paranoid schizophrenia who had exacerbation of his psychotic symptoms twice, after starting and resuming risperidone addition.

Case Report

The patient is a 52-year-old single man with a university education. He was seen at the age of 26, and at that time he manifested delusions of persecution, impulsive and aggressive behavior, and excitement. For the 26 years since then, he has been hospitalized. During hospitalization, his symptoms developed into systematized delusions. He was convinced that he was born in China as a son of the Chinese president and a Japanese mother, and that he came to Japan with Japanese soldiers after the Second World War. Also, he insisted that the Chinese government implanted 2.01 cm of metallic nail into his occipital muscle as revenge when he was a baby, and that via the metallic nail, electric waves were often conveying a command, disturbing sleep and inducing irritability. Although an X-ray of his head demonstrating there was no metallic nail was shown to him, he did not correct his thoughts at all.
He had been put on several psychotropics, including haloperidol 15 mg/day and lithium 800 mg/day (serum lithium levels: 0.4–0.7 mEq/ l), for 5 years. With these medications, he did not complain of his metallic nail spontaneously, but he did so when he was asked about its existence. Because he suffered from loss of activity and spontaneity, the medications were changed. Lithium was discontinued because it did not seem to have a significant effect in this patient, and 39 days after lithium discontinuation, risperidone 2 mg/day was added to the other drugs. After risperidone was increased to 6 mg/day over 2 weeks, unexpectedly he began to complain obstinately of his metallic nail. Furthermore, he demanded to be operated on for its removal. He also showed irritability, anxiety, and severe insomnia. Thus, risperidone was discontinued after 37 days; 10 mg of haloperidol was injected for 4 days, and haloperidol 40 mg/day po was added. The intensity of his delusions was decreased within a week.
Forty-seven days after risperidone discontinuation, risperidone 2 mg/day was resumed in order to investigate whether risperidone administration or lithium discontinuation worsened his delusions. Risperidone was increased to 6 mg/ day over 2 weeks, a pace similar to that of the previous increment, with haloperidol 40 mg/day. As a result, he again began to complain of his metallic nail persistently. Immediately, risperidone was discontinued, but he again demanded to be operated on for removal of his metallic nail. He also showed irritability, anxiety, and severe insomnia. It was necessary to add levomepromazine 50 mg/day. However, as in the previous episode, the intensity of his delusions was decreased within a week after risperidone discontinuation. Throughout the following 16 months, he did not complain of his metallic nail spontaneously.
In the present case risperidone addition to conventional neuroleptics, rather than lithium discontinuation, is likely to have exacerbated the psychotic symptoms, considering that risperidone rechallenge brought about a similar exacerbation.

References

1.
Post L: Risperidone (letter). Hosp Community Psychiatry 1994; 45:1147
2.
Byerly MJ, Greer RA, Evans DL: Behavioral stimulation associated with risperidone initiation. Am J Psychiatry 1995; 152:1096–1097
3.
O'Croinin F, Zibin T, Holt L: Re: hypomania associated with risperidone (letter). Can J Psychiatry 1995; 40:51
4.
Schnierow BJ, Graeber DA: manic symptoms associated with initiation of risperidone. Am J Psychiatry 1996; 153:1235– 1236

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 114 - 115
PubMed: 11207341

History

Published online: 1 February 2001
Published in print: February 2001

Authors

Affiliations

Takeshi Terao, M.D., Ph.D.
Hideki Kojima, M.D.
Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share